Venn diagrams at the intersection
of biology and computation

Our diverse, multidisciplinary team works with some of the world's largest biopharmaceutical companies and leading academic research Institutions to uncover new biology. We're backed by investors who share our long-term vision for what the future of biological discovery
should look like.

Core Team

Platform (Engineering)
Oded Falik
San Francisco
Scientist
Michael Wu
Menlo Park
Talent Acquisition Lead
Carol Lee
Platform (Engineering)
Jeff Chang
San Francisco
Software Engineer
Matt Alexander
Menlo Park
Platform (Research)
My Thoi
Menlo Park
Platform (Research)
Geoff Ivison
Boston
Platform (Research)
Aya Kondo
Menlo Park
Scientist
Matt Bieniosek
Platform (Research)
Will Widjaja
Remote
Platform (Research)
Alan Mitchell
Remote
Platform (Engineering)
Tomo Hasegawa
San Francisco
Platform (Research)
Alex Trevino
Menlo Park
Scientist
Ethan Baker
Boston
Platform (Research)
Rita Huang
Menlo Park
Head of Scientific Operations
Sankar Mohan
Menlo Park
Associate Scientist
Monee McGrady
Menlo Park
Platform (Engineering)
Bobby Wang
San Francisco
Associate Scientist
Steve Hamel
New York City
Leadership
Sunil Bodapati
Menlo Park
Platform (Engineering)
Amy Kang
San Francisco
Leadership
Archit Sheth-Shah
New York City
Software Engineer
Yue Dai
San Francisco
Platform (Research)
Ryan Preska
Menlo Park
Platform (Engineering)
Reed Loviska
Menlo Park
Business Operations
George Finnerty
New York City
Software Engineer
Young An
New York City
Platform (Research)
David Han
Menlo Park
Platform (Research)
Blaize D’Angio
Menlo Park
Leadership
Aaron Mayer
Menlo Park
Platform (Research)
Honesty Kim
Menlo Park
Product Manager
Adrian Sharma
Menlo Park

Advisors

Tom
 
Bumol
PhD
Allen Institute for Immunology
Laurence
 
Marton
MD
American Association of Cancer Research
Paul
 
Conley
PhD
General Inception
James
 
Allison
PhD
MD Anderson Cancer Center
James
 
Zou
PhD
Stanford University
Christian
 
Schürch
MD, PhD
University Hospital Tübingen
Padmanee
 
Sharma
MD, PhD
MD Anderson Cancer Center
Andrew
 
Lo
PhD
Massachusetts Institute of Technology

Investors